Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy: An illustrative example focusing on the primary prevention of coronary heart disease in Canada

PharmacoEconomics

Volumn 16, Issue 2, 1999, Pages 193-205

  Morris, Stephen ^a   Godber, Ed ^b  

^a CITY UNIVERSITY   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CANADA; CHOLESTEROL BLOOD LEVEL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HUMANS; RISK FACTORS;

EID: 0032842443     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916020-00008     Document Type: Article

References (23)

1. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower the risk of ischaemic heart disease? BMJ 1994; 308: 367-72
2. Morris S, McGuire A, Caro J, et al. The cost-effectiveness of strategies for the management of hypercholesterolemia: a systematic review of the cost-effectiveness literature. J Health Serv Res Pol 1997; 2: 231-50
3. Heudebert GR, Van Ruiswyk J, Hiatt J, et al. Combination therapy for hypercholesterolemia: the trade-off between cost and simplicity. Arch Intern Med 1993; 153: 1828-37
4. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA Reductase Inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994; 16: 1052-62
5. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 1990; 264: 3025-33
6. Martens LL, Belanger AJ, Finn PA, et al. Incremental cost-effectiveness of colestipol-lovastatin combination therapy versus high-dose lovastatin monotherapy in hypercholesterolemia [abstract]. Ninth meeting of the International Society of Technology Assessment in Health Care: 1993 May 25; Sorrento, Italy
7. Maclean DR, Petrasovits A, Nargundkar M. Canadian heart health surveys: a profile of cardiovascular risk. Can Med Assoc J 1992; 146 (11): 1969-2029
8. Guibert R, Contandriopoulos AP, Champagne F, et al. Cost-effectiveness analysis of lipid modulators in Canada: results and potential usefulness. Can J Cardiol 1993; 9 Suppl. D: 28D-29D
9. Oldridge N, Furlong W, Feeny D, et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol 1993; 72: 154-61
10. Pilote L, Hlatky M, Racine N. [letter]. Arch Intern Med 1995; 155: 335
11. Rousseau JL, Moye LA, Pfeffer MA, et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med 1993; 328 (11): 779-84
12. Anderson HV, Gibson RS, Stone PH, et al. Management of unstable angina pectoris and non-Q-wavew acute myocardial infarction in the United States and Canada. Am J Cardiol 1997; 79: 1441-6
13. Perreault S, Hamilton VH, Lavoie F, et al. Treating hyperlipidemia for the primary prevention of coronary disease: are higher dosages of lovastatin cost-effective? Arch Intern Med 1998; 157: 375-81
14. Oster G, Colditz GA, Kelly NL. The economic costs of smoking and benefits of quitting. Toronto: Lexington Books, 1984
15. Agency for Health Care Policy and Research. H-CUP3 Research Note, Release 3. Agency for Health Care Policy and Research; 1996 April. Report no.: 96-0047
16. Liste de médicaments (Quebec). Regie de l'assuranee maladie. Quebec, April 1998
17. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP II). Circulation 1994; 89: 1333-445
18. Betteridge DJ, Dodson PM, Durrington PN, et al. Management of hyperlipidaemia: Guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69: 359-69
19. Sheldon T. Problems of using modelling in the economic evaluation of health care. Health Economics 1996; 5: 1-11
20. Glick H, Kinosian B, Schulman K. Decision analytic modelling: Some uses in the evaluation of new pharmaceuticals. Drug Inform J 1994; 28: 691-707
21. Rittenhouse B. Uses of models in economic evaluations of medicines and other health technologies. London: Office of Health Economics, 1996
22. Morris S. Comparing economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ 1997; 6: 589-601
23. Schulte H, Assman G. CHD risk equations obtained from the Framingham Heart Study applied to PROCAM study. Cardiovasc Risk Fact 1991; 1: 126-33